GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

October 31, 2015

Conditions

Breast CancerBrain Metastases

Interventions

DRUG

GRN1005

550 mg/m2 IV every 3 weeks

DRUG

Trastuzumab

2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice

DRUG

18F-FLT

5 mCi of 18F-FLT IV during Screening and during Cycle 1

Trial Locations (2)

NCI, Rockville

Ingalls Memorial Hospital, Harvey